Intravenous Laser Blood Irradiation and Tocilizumab in a Patient with Juvenile Arthritis
This study presents effects of intravenous laser blood irradiation (ILBI) in a transient immunodeficiency patient with juvenile idiopathic arthritis (JIA) treated with an interleukin-6 receptor inhibitor (Tocilizumab). Biological agents induce JIA remission, but some patients do not respond favorabl...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2014-01-01
|
| Series: | Case Reports in Medicine |
| Online Access: | http://dx.doi.org/10.1155/2014/923496 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832567562532028416 |
|---|---|
| author | Dragos Andrei Chiran Michael Weber Laura Marinela Ailioaie Eovelina Moraru Constantin Ailioaie Daniela Litscher Gerhard Litscher |
| author_facet | Dragos Andrei Chiran Michael Weber Laura Marinela Ailioaie Eovelina Moraru Constantin Ailioaie Daniela Litscher Gerhard Litscher |
| author_sort | Dragos Andrei Chiran |
| collection | DOAJ |
| description | This study presents effects of intravenous laser blood irradiation (ILBI) in a transient immunodeficiency patient with juvenile idiopathic arthritis (JIA) treated with an interleukin-6 receptor inhibitor (Tocilizumab). Biological agents induce JIA remission, but some patients do not respond favorably to this final therapeutic line of defense. ILBI was performed in a 16-year-old male patient, with JIA and transient immunodeficiency. When ILBI was introduced, the patient was receiving disease-modifying drugs, steroids, tocilizumab, and physical therapy. Because the disease was not well controlled, ILBI was applied in addition to other ongoing therapies. The patient underwent 1 session daily, and 10 successive sessions per month, repeated every 3 months, for 7 months. Patient evaluation was performed before ILBI was started and at 3, 6, 9, and 12 months after ILBI initiation, using the ACR Pediatric response. The outcome was evaluated using Pediatric 50, 70, and 90 responses and compared to initial status, after 3, 6, 9, and 12 months. At the end of study, the titre of IgA and IgG levels returned to normal. Synergistic anti-inflammatory effect of ILBI was evident, if applied additionally in combination with tocilizumab, in a patient with a therapy-resistant severe form of JIA and related subacute transient immunodeficiency. |
| format | Article |
| id | doaj-art-07b7abd1bb834cd79bce82e311346d48 |
| institution | Kabale University |
| issn | 1687-9627 1687-9635 |
| language | English |
| publishDate | 2014-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Case Reports in Medicine |
| spelling | doaj-art-07b7abd1bb834cd79bce82e311346d482025-02-03T01:01:01ZengWileyCase Reports in Medicine1687-96271687-96352014-01-01201410.1155/2014/923496923496Intravenous Laser Blood Irradiation and Tocilizumab in a Patient with Juvenile ArthritisDragos Andrei Chiran0Michael Weber1Laura Marinela Ailioaie2Eovelina Moraru3Constantin Ailioaie4Daniela Litscher5Gerhard Litscher6Faculty of Medicine, “Grigore T. Popa” University of Medicine and Pharmacy, 16 Universitatii Street, 700115 Iasi, RomaniaInstitute for Laser Therapy and Acupuncture, Sohnreystraße 6, 37697 Lauenförde, GermanyDepartment of Medical Physics, “Alexandru Ioan Cuza” University, 11 Carol I Boulevard, 700506 Iasi, RomaniaFaculty of Medicine, “Grigore T. Popa” University of Medicine and Pharmacy, 16 Universitatii Street, 700115 Iasi, RomaniaFaculty of Medicine, “Grigore T. Popa” University of Medicine and Pharmacy, 16 Universitatii Street, 700115 Iasi, RomaniaResearch Unit of Biomedical Engineering in Anesthesia and Intensive Care Medicine and TCM Research Center Graz, Medical University of Graz, Auenbruggerplatz 29, 8036 Graz, AustriaResearch Unit of Biomedical Engineering in Anesthesia and Intensive Care Medicine and TCM Research Center Graz, Medical University of Graz, Auenbruggerplatz 29, 8036 Graz, AustriaThis study presents effects of intravenous laser blood irradiation (ILBI) in a transient immunodeficiency patient with juvenile idiopathic arthritis (JIA) treated with an interleukin-6 receptor inhibitor (Tocilizumab). Biological agents induce JIA remission, but some patients do not respond favorably to this final therapeutic line of defense. ILBI was performed in a 16-year-old male patient, with JIA and transient immunodeficiency. When ILBI was introduced, the patient was receiving disease-modifying drugs, steroids, tocilizumab, and physical therapy. Because the disease was not well controlled, ILBI was applied in addition to other ongoing therapies. The patient underwent 1 session daily, and 10 successive sessions per month, repeated every 3 months, for 7 months. Patient evaluation was performed before ILBI was started and at 3, 6, 9, and 12 months after ILBI initiation, using the ACR Pediatric response. The outcome was evaluated using Pediatric 50, 70, and 90 responses and compared to initial status, after 3, 6, 9, and 12 months. At the end of study, the titre of IgA and IgG levels returned to normal. Synergistic anti-inflammatory effect of ILBI was evident, if applied additionally in combination with tocilizumab, in a patient with a therapy-resistant severe form of JIA and related subacute transient immunodeficiency.http://dx.doi.org/10.1155/2014/923496 |
| spellingShingle | Dragos Andrei Chiran Michael Weber Laura Marinela Ailioaie Eovelina Moraru Constantin Ailioaie Daniela Litscher Gerhard Litscher Intravenous Laser Blood Irradiation and Tocilizumab in a Patient with Juvenile Arthritis Case Reports in Medicine |
| title | Intravenous Laser Blood Irradiation and Tocilizumab in a Patient with Juvenile Arthritis |
| title_full | Intravenous Laser Blood Irradiation and Tocilizumab in a Patient with Juvenile Arthritis |
| title_fullStr | Intravenous Laser Blood Irradiation and Tocilizumab in a Patient with Juvenile Arthritis |
| title_full_unstemmed | Intravenous Laser Blood Irradiation and Tocilizumab in a Patient with Juvenile Arthritis |
| title_short | Intravenous Laser Blood Irradiation and Tocilizumab in a Patient with Juvenile Arthritis |
| title_sort | intravenous laser blood irradiation and tocilizumab in a patient with juvenile arthritis |
| url | http://dx.doi.org/10.1155/2014/923496 |
| work_keys_str_mv | AT dragosandreichiran intravenouslaserbloodirradiationandtocilizumabinapatientwithjuvenilearthritis AT michaelweber intravenouslaserbloodirradiationandtocilizumabinapatientwithjuvenilearthritis AT lauramarinelaailioaie intravenouslaserbloodirradiationandtocilizumabinapatientwithjuvenilearthritis AT eovelinamoraru intravenouslaserbloodirradiationandtocilizumabinapatientwithjuvenilearthritis AT constantinailioaie intravenouslaserbloodirradiationandtocilizumabinapatientwithjuvenilearthritis AT danielalitscher intravenouslaserbloodirradiationandtocilizumabinapatientwithjuvenilearthritis AT gerhardlitscher intravenouslaserbloodirradiationandtocilizumabinapatientwithjuvenilearthritis |